Login
Sign up

[425] Sonnet BioTherapeutics Holdings, Inc. Business Combination Communication

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

425

11/12/2025 - 09:39 AM

Source: View Original Filing on SEC EDGAR

Sonnet Biotherapeutc Hldng Inc

NASDAQ:SONN

SONN Rankings

#5648 Ranked by Market Cap

N/A Ranked by Dividends

SONN Latest News

Sep 19, 2025

Sonnet to Present at the MedInvest Biotech & Pharma Conference

Aug 11, 2025

Sonnet Releases Virtual Investor "What This Means" Segment

Aug 4, 2025

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Jul 14, 2025

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

May 1, 2025

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

SONN Latest SEC Filings

Oct 27, 2025

[DEFM14A] Sonnet BioTherapeutics Holdings, Inc. Merger Proxy Statement

Sep 29, 2025

[8-K] Sonnet BioTherapeutics Holdings, Inc. Reports Material Event

Aug 26, 2025

[DEF 14A] Sonnet BioTherapeutics Holdings, Inc. Definitive Proxy Statement

Aug 21, 2025

[Form 4] Sonnet BioTherapeutics Holdings, Inc. Insider Trading Activity

Aug 13, 2025

[10-Q] Sonnet BioTherapeutics Holdings, Inc. Quarterly Earnings Report

SONN Stock Data

Market Cap 36.87M

Float 6.80M

Insiders Ownership 4.4%

Institutions Ownership 5.56%

Short Percent 27.33%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City PRINCETON